A blink is an excellent editor. It arrives every few seconds, sweeps the surface clean, and gives no respect to the business plan. For Tim Willis, that tiny mechanical interruption has supplied decades of work. He has helped create familiar eye-care products, built a medical-device company around the physics of the eyelid, raised nine figures to carry it through regulation and commercialization, and watched Johnson & Johnson Vision acquire it. Then he came back to the same neighborhood with another company.
Willis is an electro-mechanical engineer by training. His public biography does not name the school or the year, which leaves the diploma less interesting than the habit it seems to have encouraged: reduce a large complaint to a physical system that can be observed, measured, and changed. His career includes research and development, marketing, senior management, and corporate and business development. An industry biography credits him with responsibility for more than 50 product launches. EternaTear’s account is narrower and more revealing: he worked on Soothe XP, now marketed by Bausch + Lomb, and helped develop and license Systane Balance to Alcon.
Those bottles make an unusual sort of résumé. They also became the established products surrounding his next bet. Willis did not leave the category after learning it. He kept returning with a more specific question.
The first companyA treatment needed a ruler
TearScience began in September 2005. The original focus, Willis later recalled, was treatment. Two questions stood in the way. Would the treatment work? And would leading physicians and researchers accept the company’s view of evaporative dry eye and meibomian gland dysfunction? He corrected an interviewer who called these “worries.” They were concerns. The distinction is wonderfully engineered: concern can be assigned, tested, and turned into a workstream.
The company soon encountered a more basic obstacle. Existing clinical measures did not consistently connect observable signs with what patients reported. A treatment company could not build its case on a fuzzy ruler. So TearScience developed a clinical metric around meibomian glands yielding liquid secretion. The new measure became part of the company’s evidence system and, Willis said, was recognized by the FDA and used in published research.
The joke came after TearScience reviewed 33 failed clinical studies in the field. The useful detail is not bravado. It is the sequence: before asking the study to prove the treatment, the team worked on proving that its measurement could be consistent, repeatable, and reproducible. Many founders want a moat. TearScience first needed a ruler.
The long middleMoney, machines, and a market
Regulated hardware is a long conversation with several audiences at once. The device has to work. Clinicians must believe the evidence. Regulators must be able to evaluate it. Investors have to finance the gaps between milestones. Manufacturing must turn the prototype into something repeatable. TearScience’s operating history shows all of those rooms.
Its LipiFlow system used heat and directional pressure in an office-based procedure, while its diagnostic tools allowed clinicians to examine the glands and the tear film. The company pursued sequential FDA filings for different elements of the system. Willis argued at the time that attempting both together could have delayed clearance. It was a regulatory choice with an engineer’s flavor: separate the components, establish equivalence step by step, and keep the critical path moving.
Selected capital milestones · bars scaled to largest announcement
Capital did not arrive without bruises. Willis once described four venture groups reviewing a Series C. Two spent months with his scientists and clinical advisers, costing the company more than $10,000 apiece in team time. At the end, each admitted it did not have money available to invest. His distilled advice was brief: “If it doesn’t feel right, don’t do it.” Due diligence, in his telling, was not a ceremony performed on the startup alone.
By 2013, TearScience secured up to $70 million from HealthCare Royalty Partners to support global commercialization. EternaTear’s official biography says that during Willis’s tenure the company raised roughly $134 million, approved four products, launched in more than 30 countries, and obtained regulatory clearance in more than 50.
The handoffKnowing when the job changes
In 2015, Willis transferred the TearScience president and CEO roles to Joseph Boorady, then a senior commercial executive at Carl Zeiss Meditec. Willis’s public explanation was direct: Boorady had the commercial record to lead the company’s next phase of market expansion. Founders are often celebrated for refusing to let go. This was the less theatrical skill of recognizing that a company’s job had changed.
Willis continued appearing in the ophthalmology ecosystem. That same year, he joined the board of InnFocus and took charge of its external-financing committee. His network included professional affiliations with ASCRS, ARVO, and the Licensing Executive Society, as well as fellowship in the American Academy of Optometry. He was also publicly listed on the boards of Life Branch Institute and Trinity Academy.
Then came the cleanest external verdict on the company. In September 2017, Johnson & Johnson Vision completed its acquisition of TearScience. The price was not disclosed. That silence is worth preserving: an acquisition can be consequential without an invented number attached to it.
Origin skills and scale skills overlap, but they are not identical. Willis treated the CEO seat as a role the company needed, rather than a title the founder owned.
The company he keepsA repeat cast, not a solo act
The organizations around Willis reveal another kind of compounding. EternaTear’s management page pairs him with Ralph Stone, an Alcon veteran who serves as chief technology officer; Diethart Reichardt, a former Allergan consumer-products leader; operating executive Joe Huber; and finance executive Kent Geer. The company’s 2020 round added Cynthia Schwalm, Jim Murphy, and Mary Jo Potter to its board. Their backgrounds span biotech operations, Alcon’s consumer and international businesses, angel investing, and company building.
Several names and specialties recur around his later projects. Crystilex again lists Willis alongside Stone, Reichardt, and Geer, with Steve Bacich as co-founder and inventor. MED1 Ventures lists Willis and Bacich as founding partners. The arrangement is less lone genius than repertory company: technical, clinical, commercial, financial, and regulatory experience recombines around a new product.
That matters in ophthalmology, where no single résumé can carry a device or formulation through every gate. An engineer may frame the mechanism. A clinician must challenge its usefulness. A regulatory specialist turns evidence into a submission. A commercial operator understands the shelf or the practice. Capital has to arrive before each discipline can finish its work. Willis’s visible talent is not merely returning to a familiar problem. It is keeping enough trusted expertise within calling distance to make the return productive.
The returnA drop with somewhere to be
EternaTear was founded in Raleigh in 2018. The company moved from capital equipment and an office procedure toward an over-the-counter, preservative-free artificial tear. Its stated design goal is to supplement the layers of the tear film and remain on the eye longer than existing products. The claim still has to live in the disciplined world Willis knows well: formulation, testing, manufacturing, regulatory registration, and a market study.
In October 2020, EternaTear announced a $4.9 million oversubscribed Series A. Carolina Angel Network and Keiretsu Forum led the round, joined by Band of Angels, Deep Work Capital, Duke Angel Network, Keiretsu Capital, and strategic clinicians and entrepreneurs. The use of proceeds was practical rather than decorative: refine the product, validate a multidose non-preserved bottle, complete a multisite study, register the OTC product with the FDA, and scale manufacturing.
Willis also said the quiet part in public. The board would help drive the company toward its objectives, “including, ultimately, a successful market exit.” There is no coy romance about permanence here. A medical-product startup can be built to answer a clinical question and to become useful to a larger strategic owner. TearScience had already demonstrated that arc.
The patternPerspiration with a schematic
Willis once compressed entrepreneurship into an old ratio: “1 percent idea and 99 percent perspiration.” His version adds that founders need a passion for the perspiration. The line fits a career where the glamorous nouns - invention, founder, acquisition - depend on less glamorous verbs: measure, file, validate, manufacture, raise, launch, repeat.
His current public roles widen the picture without changing it. MED1 Ventures lists him as a founding partner working on medical-device companies. Crystilex lists him as a co-founder and inventor on another ophthalmic program. EternaTear still names him CEO and chairman. These are not departures from a thesis so much as adjacent benches in the same workshop.
There is a useful founder lesson in that concentration. Expertise compounds when the next project is close enough to reuse relationships, regulatory knowledge, and scar tissue, but different enough to pose a new technical question. Willis’s career has stayed within a tiny physical territory while repeatedly changing the instrument brought to it: a formulation, a diagnostic image, heat and pressure, a clinical metric, another formulation.
The blink remains unimpressed. It will keep arriving, sweeping the surface, and testing every claim. For an engineer, that may be the attraction. The problem never applauds. It merely gives another result.